Reply to: “Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations”?

Matthew Surface; Manisha Balwani; Cheryl Waters; Alexander Haimovich; Ziv Gan-Or; Karen S. Marder; Tammy Hsieh; Linxia Song; Shalini Padmanabhan; Frank Hsieh; Kalpana M. Merchant; Roy N. Alcalay

doi:10.1002/mds.29136

Reply to: “Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations”?

Matthew Surface, Manisha Balwani, Cheryl Waters, Alexander Haimovich, Ziv Gan-Or, Karen S. Marder, Tammy Hsieh, Linxia Song, Shalini Padmanabhan, Frank Hsieh, Kalpana M. Merchant, Roy N. Alcalay

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1782
Number of pages	1
Journal	Movement Disorders
Volume	37
Issue number	8
DOIs	https://doi.org/10.1002/mds.29136
State	Published - Aug 2022

Access to Document

10.1002/mds.29136

Cite this

@article{c90dad132c05452e9551534f4530bfda,

title = "Reply to: “Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations”?",

author = "Matthew Surface and Manisha Balwani and Cheryl Waters and Alexander Haimovich and Ziv Gan-Or and Marder, {Karen S.} and Tammy Hsieh and Linxia Song and Shalini Padmanabhan and Frank Hsieh and Merchant, {Kalpana M.} and Alcalay, {Roy N.}",

note = "Funding Information: The authors have no financial disclosures or conflicts of interest to report. Disclosures unrelated to the study: Manisha Balwani: Research support (NIH/NIDDK, Genzyme, Alnylam, Mitsubishi‐Tanabe), Honoraria (Genzyme, Takeda, Alnylam, Prevail, Freeline, Alexion). Cheryl Waters: Research support (Biogen, Roche, Sanofi); consulting fees ( Kyowa, Alexza, Sunovion); speaker's honoraria (Acadia, Acorda, Adamas, Amneal, Kyowa, Neurocrine, US WorldMeds). Ziv Gan Or: Research support (Michael J. Fox Foundation, Fonds de recherche du Qu{\'e}bec – Sant{\'e}, Canadian Consortium for Neurodegeneration in Aging, Canada First Research Excellence Fund through the Healthy Brain for Healthy Lives project); Consulting fees (Denali, Inception Sciences (now Ventus), Idorsia, Lysosomal Therapeutics Inc., Prevail Therapeutics, Deerfield, Lighthouse, Neuron23, Ono Therapeutics, Handl Therapeutics and Bial Biotech Inc).; Tammy Hsieh, Linxia Song and Frank Hsieh are employed by nextcea Inc. Kalpana Merchant: research support from the Michael J Fox Foundation, advisor/paid consultant to Michael J Fox Foundation, Caraway Therapeutics, Sinopia Biosciences, Nitrome, NuraBio, Retromer Therapeutics. Roy N. Alcalay RNA is funded by the NIH, DoD, the Parkinson's Foundation and the Michael. J. Fox Foundation. He received consultation fees from Avrobio, Caraway, GSK, Merck, Ono Therapeutics Takeda and Sanofi. Funding Information: The authors have no financial disclosures or conflicts of interest to report. Disclosures unrelated to the study: Manisha Balwani: Research support (NIH/NIDDK, Genzyme, Alnylam, Mitsubishi-Tanabe), Honoraria (Genzyme, Takeda, Alnylam, Prevail, Freeline, Alexion). Cheryl Waters: Research support (Biogen, Roche, Sanofi); consulting fees (Kyowa, Alexza, Sunovion); speaker's honoraria (Acadia, Acorda, Adamas, Amneal, Kyowa, Neurocrine, US WorldMeds). Ziv Gan Or: Research support (Michael J. Fox Foundation, Fonds de recherche du Qu{\'e}bec – Sant{\'e}, Canadian Consortium for Neurodegeneration in Aging, Canada First Research Excellence Fund through the Healthy Brain for Healthy Lives project); Consulting fees (Denali, Inception Sciences (now Ventus), Idorsia, Lysosomal Therapeutics Inc., Prevail Therapeutics, Deerfield, Lighthouse, Neuron23, Ono Therapeutics, Handl Therapeutics and Bial Biotech Inc).; Tammy Hsieh, Linxia Song and Frank Hsieh are employed by nextcea Inc. Kalpana Merchant: research support from the Michael J Fox Foundation, advisor/paid consultant to Michael J Fox Foundation, Caraway Therapeutics, Sinopia Biosciences, Nitrome, NuraBio, Retromer Therapeutics. Roy N. Alcalay RNA is funded by the NIH, DoD, the Parkinson's Foundation and the Michael. J. Fox Foundation. He received consultation fees from Avrobio, Caraway, GSK, Merck, Ono Therapeutics Takeda and Sanofi.",

year = "2022",

month = aug,

doi = "10.1002/mds.29136",

language = "English",

volume = "37",

pages = "1782",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley & Sons Inc.",

number = "8",

}

TY - JOUR

T1 - Reply to

T2 - “Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations”?

AU - Surface, Matthew

AU - Balwani, Manisha

AU - Waters, Cheryl

AU - Haimovich, Alexander

AU - Gan-Or, Ziv

AU - Marder, Karen S.

AU - Hsieh, Tammy

AU - Song, Linxia

AU - Padmanabhan, Shalini

AU - Hsieh, Frank

AU - Merchant, Kalpana M.

AU - Alcalay, Roy N.

N1 - Funding Information: The authors have no financial disclosures or conflicts of interest to report. Disclosures unrelated to the study: Manisha Balwani: Research support (NIH/NIDDK, Genzyme, Alnylam, Mitsubishi‐Tanabe), Honoraria (Genzyme, Takeda, Alnylam, Prevail, Freeline, Alexion). Cheryl Waters: Research support (Biogen, Roche, Sanofi); consulting fees ( Kyowa, Alexza, Sunovion); speaker's honoraria (Acadia, Acorda, Adamas, Amneal, Kyowa, Neurocrine, US WorldMeds). Ziv Gan Or: Research support (Michael J. Fox Foundation, Fonds de recherche du Québec – Santé, Canadian Consortium for Neurodegeneration in Aging, Canada First Research Excellence Fund through the Healthy Brain for Healthy Lives project); Consulting fees (Denali, Inception Sciences (now Ventus), Idorsia, Lysosomal Therapeutics Inc., Prevail Therapeutics, Deerfield, Lighthouse, Neuron23, Ono Therapeutics, Handl Therapeutics and Bial Biotech Inc).; Tammy Hsieh, Linxia Song and Frank Hsieh are employed by nextcea Inc. Kalpana Merchant: research support from the Michael J Fox Foundation, advisor/paid consultant to Michael J Fox Foundation, Caraway Therapeutics, Sinopia Biosciences, Nitrome, NuraBio, Retromer Therapeutics. Roy N. Alcalay RNA is funded by the NIH, DoD, the Parkinson's Foundation and the Michael. J. Fox Foundation. He received consultation fees from Avrobio, Caraway, GSK, Merck, Ono Therapeutics Takeda and Sanofi. Funding Information: The authors have no financial disclosures or conflicts of interest to report. Disclosures unrelated to the study: Manisha Balwani: Research support (NIH/NIDDK, Genzyme, Alnylam, Mitsubishi-Tanabe), Honoraria (Genzyme, Takeda, Alnylam, Prevail, Freeline, Alexion). Cheryl Waters: Research support (Biogen, Roche, Sanofi); consulting fees (Kyowa, Alexza, Sunovion); speaker's honoraria (Acadia, Acorda, Adamas, Amneal, Kyowa, Neurocrine, US WorldMeds). Ziv Gan Or: Research support (Michael J. Fox Foundation, Fonds de recherche du Québec – Santé, Canadian Consortium for Neurodegeneration in Aging, Canada First Research Excellence Fund through the Healthy Brain for Healthy Lives project); Consulting fees (Denali, Inception Sciences (now Ventus), Idorsia, Lysosomal Therapeutics Inc., Prevail Therapeutics, Deerfield, Lighthouse, Neuron23, Ono Therapeutics, Handl Therapeutics and Bial Biotech Inc).; Tammy Hsieh, Linxia Song and Frank Hsieh are employed by nextcea Inc. Kalpana Merchant: research support from the Michael J Fox Foundation, advisor/paid consultant to Michael J Fox Foundation, Caraway Therapeutics, Sinopia Biosciences, Nitrome, NuraBio, Retromer Therapeutics. Roy N. Alcalay RNA is funded by the NIH, DoD, the Parkinson's Foundation and the Michael. J. Fox Foundation. He received consultation fees from Avrobio, Caraway, GSK, Merck, Ono Therapeutics Takeda and Sanofi.

PY - 2022/8

Y1 - 2022/8

UR - http://www.scopus.com/inward/record.url?scp=85135990167&partnerID=8YFLogxK

U2 - 10.1002/mds.29136

DO - 10.1002/mds.29136

M3 - Letter

C2 - 35980035

AN - SCOPUS:85135990167

SN - 0885-3185

VL - 37

SP - 1782

JO - Movement Disorders

JF - Movement Disorders

IS - 8

ER -